Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 42% ± 18% | |
peripheral blood | 18 studies | 68% ± 17% | |
intestine | 11 studies | 43% ± 29% | |
kidney | 7 studies | 45% ± 21% | |
brain | 7 studies | 28% ± 7% | |
eye | 5 studies | 31% ± 14% | |
liver | 4 studies | 46% ± 23% | |
bone marrow | 4 studies | 42% ± 27% | |
heart | 4 studies | 19% ± 4% | |
uterus | 4 studies | 40% ± 9% | |
adipose | 4 studies | 36% ± 28% | |
lymph node | 4 studies | 76% ± 17% | |
breast | 4 studies | 40% ± 12% | |
skin | 4 studies | 31% ± 8% | |
adrenal gland | 3 studies | 52% ± 27% | |
esophagus | 3 studies | 39% ± 16% | |
prostate | 3 studies | 24% ± 5% | |
thymus | 3 studies | 32% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 98% | 18978.96 | 254 / 258 | 99% | 156.02 | 227 / 230 |
thymus | 96% | 27117.93 | 627 / 653 | 100% | 154.60 | 602 / 605 |
prostate | 95% | 33878.21 | 233 / 245 | 100% | 189.19 | 501 / 502 |
breast | 98% | 38813.70 | 450 / 459 | 95% | 128.47 | 1064 / 1118 |
lung | 96% | 41529.77 | 552 / 578 | 93% | 115.28 | 1078 / 1155 |
uterus | 85% | 26285.64 | 144 / 170 | 90% | 77.23 | 412 / 459 |
kidney | 78% | 12894.99 | 69 / 89 | 93% | 187.90 | 838 / 901 |
bladder | 90% | 43410.71 | 19 / 21 | 79% | 59.13 | 396 / 504 |
skin | 86% | 29317.53 | 1560 / 1809 | 80% | 60.23 | 377 / 472 |
esophagus | 87% | 26144.05 | 1251 / 1445 | 77% | 50.55 | 140 / 183 |
stomach | 93% | 24337.20 | 334 / 359 | 70% | 41.89 | 199 / 286 |
ovary | 92% | 28283.59 | 165 / 180 | 69% | 35.99 | 297 / 430 |
intestine | 89% | 25592.63 | 862 / 966 | 61% | 36.74 | 319 / 527 |
brain | 39% | 4230.89 | 1037 / 2642 | 99% | 100.96 | 700 / 705 |
pancreas | 26% | 2776.48 | 85 / 328 | 94% | 175.15 | 168 / 178 |
liver | 35% | 4832.16 | 80 / 226 | 66% | 58.73 | 268 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 115.15 | 29 / 29 |
ureter | 0% | 0 | 0 / 0 | 100% | 68.59 | 1 / 1 |
blood vessel | 99% | 60954.42 | 1320 / 1335 | 0% | 0 | 0 / 0 |
adipose | 98% | 39539.41 | 1178 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 96.44 | 43 / 45 |
spleen | 95% | 32222.86 | 229 / 241 | 0% | 0 | 0 / 0 |
muscle | 90% | 38542.63 | 719 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 86% | 42940.61 | 802 / 929 | 0% | 0 | 0 / 0 |
heart | 67% | 12429.71 | 573 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 26% | 9.27 | 21 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006970 | Biological process | response to osmotic stress |
GO_0070236 | Biological process | negative regulation of activation-induced cell death of T cells |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | TSC22D3 |
Protein name | TSC22 domain family protein 3 TSC22 domain family protein 3 (DSIP-immunoreactive peptide) (Protein DIP) (hDIP) (Delta sleep-inducing peptide immunoreactor) (Glucocorticoid-induced leucine zipper protein) (GILZ) (TSC-22-like protein) (TSC-22-related protein) (TSC-22R) TSC22 domain family member 3 |
Synonyms | DSIPI GILZ |
Description | FUNCTION: Protects T-cells from IL2 deprivation-induced apoptosis through the inhibition of FOXO3A transcriptional activity that leads to the down-regulation of the pro-apoptotic factor BCL2L11 . In macrophages, plays a role in the anti-inflammatory and immunosuppressive effects of glucocorticoids and IL10 . In T-cells, inhibits anti-CD3-induced NFKB1 nuclear translocation and thereby NFKB1 DNA-binding activities . In vitro, suppresses AP-1 transcription factor complex DNA-binding activities (By similarity). .; FUNCTION: [Isoform 1]: Inhibits myogenic differentiation and mediates anti-myogenic effects of glucocorticoids by binding and regulating MYOD1 and HDAC1 transcriptional activity resulting in reduced expression of MYOG. . |
Accessions | ENST00000506081.5 [Q99576-3] ENST00000315660.8 [Q99576-3] ENST00000372397.6 [Q99576-1] E7EWD5 ENST00000372382.8 Q99576 ENST00000372383.9 [Q99576-3] ENST00000372390.8 [Q99576-5] ENST00000510887.5 D6RDZ7 D6RDZ9 ENST00000503515.1 D6RD37 ENST00000486554.1 A0A8I5KT94 D6RBL1 ENST00000480691.2 Q5JRJ0 ENST00000502961.1 D6R8Z7 ENST00000372384.6 [Q99576-3] D6RCK9 D6RAX8 ENST00000514426.1 ENST00000502650.1 D6R9J1 ENST00000514897.5 D6RD92 ENST00000506724.1 ENST00000688924.1 ENST00000505965.1 |